DMAAR vs TXT · $1.8M cap vs P/E 19, rev $7.52B
Drugs Made In America Acquisition Corp. Rights (DMAAR) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Drugs Made In America Acquisition Corp. Rights (DMAAR) common stock listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
DMAAR does not have a complete income-statement cache yet.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
DMAAR currently screens at market cap $1.8M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the DMAAR and TXT stock pages for the full models.
Not investment advice.